ROCKVILLE, MD and SHENZHEN, CHINA, Nov 17, 2022 – (ACN Newswire via SEAPRWire.com) – HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing …
American Journal of Gastroenterology Publishes Data from HighTide Therapeutics’ Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis
ROCKVILLE, MD and SHENZHEN, CHINA, Nov 16, 2022 – (ACN Newswire via SEAPRWire.com) – HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing …